{
  "ticker": "LLY",
  "target_date": "2025-11-17",
  "actual_date": "2025-11-17",
  "collected_at": "2025-12-08T12:32:37.452333",
  "price": {
    "open": 1003.72,
    "high": 1032.14,
    "low": 998.3,
    "close": 1021.7000122070312,
    "volume": 4720000,
    "change_1d_pct": -0.35,
    "change_7d_pct": 9.15,
    "change_30d_pct": 21.08
  },
  "technicals": {
    "rsi_14": 90.69,
    "sma_20": 901.82,
    "sma_50": 831.54,
    "macd": 57.266,
    "macd_signal": 44.66,
    "macd_histogram": 12.606,
    "bb_upper": 1065.94,
    "bb_lower": 737.69,
    "price_vs_sma20_pct": 13.29,
    "price_vs_sma50_pct": 22.87,
    "volume_ratio": 1.09
  },
  "fundamentals": {
    "market_cap": 892341977088,
    "pe_ratio": 48.7707,
    "forward_pe": 43.928066,
    "price_to_book": 37.477787,
    "price_to_sales": 15.017587,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.48,
    "pct_from_52w_low": 59.58
  },
  "macro": {
    "spy": {
      "price": 665.67,
      "change_1d_pct": -0.93,
      "change_7d_pct": -0.79
    },
    "vix": {
      "level": 22.38,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.13
    },
    "dollar_index": {
      "level": 99.59
    },
    "gold": {
      "price": 4068.3
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly Partner And Cancer Treatment Maker Nears Buy Point",
      "source": "Yahoo",
      "datetime": 1763405087,
      "summary": "This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.",
      "url": "https://finnhub.io/api/news?id=6db04e45e76e8db02ca5a9cb90e941d685d83ff62c78c1f028224ba309279d03"
    },
    {
      "headline": "How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration",
      "source": "Yahoo",
      "datetime": 1763399274,
      "summary": "Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.",
      "url": "https://finnhub.io/api/news?id=21b472c5106e43c25a9415b924933f827dd75994b9361f36cdd5896616769957"
    },
    {
      "headline": "Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It\u2019s a Worry for the Stocks.",
      "source": "Yahoo",
      "datetime": 1763396520,
      "summary": "Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.",
      "url": "https://finnhub.io/api/news?id=9803dc282d2f71959a5ebab4b246083e745254f5694c2a551871b5224c6f447d"
    },
    {
      "headline": "NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?",
      "source": "Yahoo",
      "datetime": 1763393040,
      "summary": "Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.",
      "url": "https://finnhub.io/api/news?id=544ad70a57aaa80ffd74596bc5b43055b057792286403aa452e12ed6efc9073e"
    },
    {
      "headline": "Eli Lilly Could Be Next Company to Split Its Stock",
      "source": "Yahoo",
      "datetime": 1763388300,
      "summary": "The drugmaker\u2019s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it\u2019s a bull market.",
      "url": "https://finnhub.io/api/news?id=5f0d331e1633811d3f46a1a03f46905b4ce7878dabd760691263cbfe65da4dfd"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-11-17",
      "description": "xslF345X05/form4-11172025_041103.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000073/xslF345X05/form4-11172025_041103.xml"
    },
    {
      "form": "4",
      "date": "2025-11-14",
      "description": "xslF345X05/form4-11142025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000071/xslF345X05/form4-11142025_041101.xml"
    },
    {
      "form": "4",
      "date": "2025-11-13",
      "description": "xslF345X05/wk-form4_1763068481.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000156153925000006/xslF345X05/wk-form4_1763068481.xml"
    },
    {
      "form": "4",
      "date": "2025-11-13",
      "description": "xslF345X05/form4-11132025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000069/xslF345X05/form4-11132025_041101.xml"
    },
    {
      "form": "4",
      "date": "2025-11-12",
      "description": "xslF345X05/form4-11122025_041107.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000065/xslF345X05/form4-11122025_041107.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}